{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T11:04:15Z","timestamp":1772017455511,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"am","delay-in-days":360,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJSP2135"],"award-info":[{"award-number":["JPMJSP2135"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018502","name":"Kanazawa University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018502","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.dmpk.2024.101025","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T22:15:30Z","timestamp":1718230530000},"page":"101025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Iminium ion metabolites are formed from nintedanib by human CYP3A4"],"prefix":"10.1016","volume":"57","author":[{"given":"Shimon","family":"Nakashima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuki","family":"Fukami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9884-2768","authenticated-orcid":false,"given":"Masataka","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9787-836X","authenticated-orcid":false,"given":"Naoki","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2024.101025_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.dmpk.2024.101025_bib2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/ph15050645","article-title":"Liver injury with nintedanib: a pharmacovigilance-pharmacokinetic appraisal","volume":"15","author":"Raschi","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.dmpk.2024.101025_bib3","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","article-title":"Drug-induced liver injury: recent advances in diagnosis and risk assessment","volume":"66","author":"Kullak-Ublick","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.dmpk.2024.101025_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/hep.20312","article-title":"Acetaminophen hepatoxicity: what do we know, what don't we know, and what do we do next?","volume":"40","author":"Kaplowitz","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dmpk.2024.101025_bib5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1124\/dmd.122.001113","article-title":"Characterization of enzymes involved in nintedanib metabolism in humans","volume":"51","author":"Nakashima","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2024.101025_bib6","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40262-019-00766-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of nintedanib","volume":"58","author":"Wind","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmpk.2024.101025_bib7","doi-asserted-by":"crossref","unstructured":"Sawamura R, Okudaira N, Watanabe K, Murai T, Kobayashi Y, Tachibana M, Ohnuki T, Masuda K, Honma H, Kurihara A, and Okazaki O. Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug Metab Dispos 38: 1857-1864.","DOI":"10.1124\/dmd.110.034173"},{"key":"10.1016\/j.dmpk.2024.101025_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/00498254.2010.545452","article-title":"Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers","volume":"41","author":"Stopfer","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmpk.2024.101025_bib9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/03602532.2014.924962","article-title":"Biotransformation and bioactivation reactions of alicyclic amines in drug molecules","volume":"46","author":"Bolleddula","year":"2014","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.dmpk.2024.101025_bib10","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1080\/00498254.2021.2007553","article-title":"Pirfenidone 5-hydroxylation is mainly catalysed by CYP1A2 and partly catalysed by CYP2C19 and CYP2D6 in the human liver","volume":"51","author":"Zhang","year":"2021","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmpk.2024.101025_bib11","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1124\/dmd.122.001198","article-title":"Development and validation of a proteomic correlation profiling technique to detect and identify enzymes involved in metabolism of drugs of concern","volume":"51","author":"Kudo","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2024.101025_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.dmpk.2017.06.002","article-title":"Monoamine oxidase B oxidizes a novel multikinase inhibitor KW-2449 to its iminium ion and aldehyde oxidase further converts it to the oxo-piperazine form in human","volume":"32","author":"Hosogi","year":"2017","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.dmpk.2024.101025_bib13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1124\/dmd.112.050484","article-title":"Characterization of human cytochrome P450s involved in the bioactivation of clozapine","volume":"41","author":"Dragovic","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2024.101025_bib14","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1124\/dmd.108.020545","article-title":"Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug","volume":"36","author":"Bauman","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2024.101025_bib15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1021\/tx300418w","article-title":"Bioactivation of the cannabinoid receptor antagonist rimonabant to a cytotoxic iminium ion metabolite","volume":"26","author":"Foster","year":"2013","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.dmpk.2024.101025_bib16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13318-018-0467-9","article-title":"Effects of ketoconazole and rifampicin on the pharmacokinetics of nintedanib in healthy subjects","volume":"43","author":"Luedtke","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2024.101025_bib17","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.bbadis.2011.01.014","article-title":"Nuclear receptor PXR, transcriptional circuits and metabolic relevance","volume":"1812","author":"Ihunnah","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.dmpk.2024.101025_bib18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1248\/yakushi.122.339","article-title":"Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR","volume":"22","author":"Nishimura","year":"2002","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.dmpk.2024.101025_bib19","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.3390\/ijms22073441","article-title":"Idiosyncratic drug induced liver injury, cytochrome P450, metabolic risk factors and lipophilicity: highlights and controversies","volume":"22","author":"Teschke","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dmpk.2024.101025_bib20","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.3390\/molecules25112718","article-title":"Liquid chromatography-tandem mass spectrometry (LC-MS\/MS)-based proteomics of drug-metabolizing enzymes and transporters","volume":"25","author":"Li","year":"2020","journal-title":"Molecules"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436724000314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436724000314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T05:33:21Z","timestamp":1730871201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436724000314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":20,"alternative-id":["S1347436724000314"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2024.101025","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Iminium ion metabolites are formed from nintedanib by human CYP3A4","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2024.101025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd on behalf of The Japanese Society for the Study of Xenobiotics.","name":"copyright","label":"Copyright"}],"article-number":"101025"}}